NTP-mediated nucleotide excision activity of hepatitis C virus RNA-dependent RNA polymerase

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 5, 2013, Pages

  Jin, Zhinan ^a   Leveque, Vincent ^a   Ma, Han ^a   Johnson, Kenneth A ^b   Klumpp, Klaus ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Drug resistance; NS5B; Nucleoside analog; Pre steady state kinetics; Pyrophosphorolysis

Indexed keywords

3' DEOXY CYTIDINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CYTIDINE PHOSPHATE; CYTIDINE TRIPHOSPHATE; DINUCLEOSIDE TETRAPHOSPHATE; RNA; RNA DIRECTED RNA POLYMERASE; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG POTENCY; DRUG RESISTANCE; EXCISION REPAIR; HEPATITIS C VIRUS; KINETICS; PRIORITY JOURNAL; PYROPHOSPHOROLYSIS; RNA REPLICATION; TRANSCRIPTION ELONGATION;

ADENOSINE TRIPHOSPHATE; BASE SEQUENCE; CYTIDINE MONOPHOSPHATE; CYTIDINE TRIPHOSPHATE; DINUCLEOSIDE PHOSPHATES; HEPACIVIRUS; HIV REVERSE TRANSCRIPTASE; KINETICS; MODELS, CHEMICAL; MODELS, GENETIC; NUCLEOTIDES; RNA REPLICASE; RNA, VIRAL; URIDINE TRIPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84873199670     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1214924110     Document Type: Article

References (47)

1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection:2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54(4):1433-1444.
2. Hofmann WP, Zeuzem S (2011) A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 8(5):257-264.
3. Lee LY, Tong CY, Wong T, Wilkinson M (2012) New therapies for chronic hepatitis C infection: A systematic review of evidence from clinical trials. Int J Clin Pract 66(4):342-355.
4. McCown MF, et al. (2008) The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 52(5):1604-1612. (Pubitemid 351614649)
5. Farnik H, Zeuzem S (2012) New antiviral therapies in the management of HCV infection. Antivir Ther 17(5):771-783.
6. Lesburg CA, et al. (1999) Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 6(10):937-943. (Pubitemid 29463307)
7. Bressanelli S, et al. (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA 96(23):13034-13039.
8. Dutartre H, Boretto J, Guillemot JC, Canard B (2005) A relaxed discrimination of 2'-O-methyl-GTP relative to GTP between de novo and Elongative RNA synthesis by the hepatitis C RNA-dependent RNA polymerase NS5B. J Biol Chem 280(8):6359-6368. (Pubitemid 40341182)
9. Cramer J, Jaeger J, Restle T (2006) Biochemical and pre-steady-state kinetic characterization of the hepatitis C virus RNA polymerase (NS5BDelta21, HC-J4). Biochemistry 45(11):3610-3619.
10. Selisko B, et al. (2006) Comparative mechanistic studies of de novo RNA synthesis by flavivirus RNA-dependent RNA polymerases. Virology 351(1):145-158. (Pubitemid 44056063)
11. Jin Z, Leveque V, Ma H, Johnson KA, Klumpp K (2012) Assembly, purification, and presteady-state kinetic analysis of active RNA-dependent RNA polymerase elongation complex. J Biol Chem 287(13):10674-10683.
12. Carroll SS, et al. (2000) Only a small fraction of purified hepatitis C RNA-dependent RNA polymerase is catalytically competent: Implications for viral replication and in vitro assays. Biochemistry 39(28):8243-8249. (Pubitemid 30460975)
13. Liu Y, et al. (2006) Mechanistic study of HCV polymerase inhibitors at individual steps of the polymerization reaction. Biochemistry 45(38):11312-11323. (Pubitemid 44453979)
14. Powdrill MH, et al. (2011) Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci USA 108(51):20509-20513.
15. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA (1999) A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 4(1):35-43. (Pubitemid 29386129)
16. Meyer PR, Matsuura SE, So AG, Scott WA (1998) Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 95(23):13471-13476. (Pubitemid 28522996)
17. Kerr SG, Anderson KS (1997) Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: Implication of RNA directed DNA polymerization in the mechanism of AZT resistance. Biochemistry 36(46):14064-14070. (Pubitemid 27509841)
18. Smith AJ, Meyer PR, Asthana D, Ashman MR, Scott WA (2005) Intracellular substrates for the primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: Detection and quantitation in extracts from quiescent-and activatedlymphocyte subpopulations. Antimicrob Agents Chemother 49(5):1761-1769. (Pubitemid 40631586)
19. Jeeninga RE, Keulen W, Boucher C, Sanders RW, Berkhout B (2001) Evolution of AZT resistance in HIV-1: The 41-70 intermediate that is not observed in vivo has a replication defect. Virology 283(2):294-305. (Pubitemid 32881176)
20. Kisselev LL, Justesen J, Wolfson AD, Frolova LY (1998) Diadenosine oligophosphates (Ap (n) A), a novel class of signalling molecules? FEBS Lett 427(2):157-163. (Pubitemid 28225049)
21. McLennan AG (2000) Dinucleoside polyphosphates-friend or foe? Pharmacol Ther 87(2-3):73-89.
22. Sillero M A G, Madrid O, Zaera E, Sillero A (1997) 2', 3'-dideoxynucleoside triphosphates (ddNTP) and di-2', 3'-dideoxynucleoside tetraphosphates (ddNp4ddN) behave differently to the corresponding NTP and Np4N counterparts as substrates of firefly luciferase, dinucleoside tetraphosphatase and phosphodiesterases. Biochim Biophys Acta 1334(2-3):191-199. (Pubitemid 27117521)
23. Tong W, et al. (1997) Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. Biochemistry 36(19):5749-5757. (Pubitemid 27214926)
24. Sosunov VV, Victorova LS (2004) [Nucleotide-dependent degradation of nucleic acids by DNA and RNA pPolymerases]. Mol Biol (Mosk) 38(5):804-822. Russian. (Pubitemid 44253023)
25. D'Abramo CM, Cellai L, Götte M (2004) Excision of incorporated nucleotide analogue chain-terminators can diminish their inhibitory effects on viral RNA-dependent RNA polymerases. J Mol Biol 337(1):1-14. (Pubitemid 38270244)
26. Meyer PR, Smith AJ, Matsuura SE, Scott WA (2004) Effects of primer-template sequence on ATP-dependent removal of chain-terminating nucleotide analogues by HIV-1 reverse transcriptase. J Biol Chem 279(44):45389-45398. (Pubitemid 39491522)
27. Doublié S, Tabor S, Long AM, Richardson CC, Ellenberger T (1998) Crystal structure of a bacteriophage T7 DNA replication complex at 2.2 A resolution. Nature 391(6664):251-258. (Pubitemid 28099004)
28. Tsai Y-C, Johnson KA (2006) A new paradigm for DNA polymerase specificity. Biochemistry 45(32):9675-9687. (Pubitemid 44257415)
29. Jin Z, Johnson KA (2011) Role of a GAG hinge in the nucleotide-induced conformational change governing nucleotide specificity by T7 DNA polymerase. J Biol Chem 286(2):1312-1322.
30. Traut TW (1994) Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 140(1):1-22. (Pubitemid 24379884)
31. Sarafianos SG, et al. (2003) Trapping HIV-1 reverse transcriptase before and after translocation on DNA. J Biol Chem 278(18):16280-16288. (Pubitemid 36799753)
32. Sarafianos SG, et al. (2002) Structures of HIV-1 reverse transcriptase with pre-and post-translocation AZTMP-terminated DNA. EMBO J 21(23):6614-6624. (Pubitemid 35448438)
33. Marchand B, Götte M (2003) Site-specific footprinting reveals differences in the translocation status of HIV-1 reverse transcriptase. Implications for polymerase translocation and drug resistance. J Biol Chem 278(37):35362-35372. (Pubitemid 37102305)
34. Mosley RT, et al. (2012) Structure of hepatitis C virus polymerase in complex with primer-template RNA. J Virol 86(12):6503-6511.
35. Dharmasena S, Pongracz Z, Arnold E, Sarafianos SG, Parniak MA (2007) 3'-Azido-3'-deoxythymidine-(5')-tetraphospho-(5')-adenosine, the product of ATP-mediated excision of chain-terminating AZTMP, is a potent chain-terminating substrate for HIV-1 reverse transcriptase. Biochemistry 46(3):828-836. (Pubitemid 46133599)
36. Meyer PR, Smith AJ, Matsuura SE, Scott WA (2006) Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogueresistant mutants. Antimicrob Agents Chemother 50(11):3607-3614. (Pubitemid 44684871)
37. Johnson AA, Johnson KA (2001) Exonuclease proofreading by human mitochondrial DNA polymerase. J Biol Chem 276(41):38097-38107.
38. Deval J, Powdrill MH, D'Abramo CM, Cellai L, Götte M (2007) Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 51(8):2920-2928. (Pubitemid 47206231)
39. Powdrill MH, Deval J, Narjes F, De Francesco R, Götte M (2010) Mechanism of hepatitis C virus RNA polymerase inhibition with dihydroxypyrimidines. Antimicrob Agents Chemother 54(3):977-983.
40. Tu X, et al. (2010) Structural basis of HIV-1 resistance to AZT by excision. Nat Struct Mol Biol 17(10):1202-1209.
41. Lam AM, et al. (2011) Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA. J Virol 85(23):12334-12342.
42. Klumpp K, et al. (2008) 2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-α-hydroxyl groups. J Biol Chem 283(4):2167-2175.
43. Ali S, et al. (2008) Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother 52(12):4356-4369.
44. Meyer PR, Matsuura SE, Schinazi RF, So AG, Scott WA (2000) Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates. Antimicrob Agents Chemother 44(12):3465-3472. (Pubitemid 33009515)
45. Boyer PL, Sarafianos SG, Arnold E, Hughes SH (2001) Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 75(10):4832-4842. (Pubitemid 32381526)
46. Johnson KA, Simpson ZB, Blom T (2009) FitSpace explorer: An algorithm to evaluate multidimensional parameter space in fitting kinetic data. Anal Biochem 387(1):30-41.
47. Johnson KA, Simpson ZB, Blom T (2009) Global kinetic explorer: a new computer program for dynamic simulation and fitting of kinetic data. Anal Biochem 387(1):20-29.